Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Grape King Bio's share price for the quarter that ended in Mar. 2026 was NT$121. Grape King Bio's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 148 Mil. Therefore, Grape King Bio's market cap for the quarter that ended in Mar. 2026 was NT$17,925 Mil.
Grape King Bio's quarterly market cap
declined
from Sep. 2025 (NT$19,258 Mil) to Dec. 2025 (NT$18,739 Mil) and
declined
from Dec. 2025 (NT$18,739 Mil) to Mar. 2026 (NT$17,925 Mil).
Grape King Bio's annual market cap
declined
from Dec. 2023 (NT$23,109 Mil) to Dec. 2024 (NT$22,146 Mil) and
declined
from Dec. 2024 (NT$22,146 Mil) to Dec. 2025 (NT$18,739 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Grape King Bio's Enterprise Value for Today is NT$11,293 Mil.
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Grape King Bio Market Cap Related Terms
Grape King Bio Market Cap Historical Data
* Premium members only.
The historical data trend for Grape King Bio's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Grape King Bio's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Grape King Bio Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Grape King Bio's Market Cap distribution charts can be found below:
* The bar in red indicates where Grape King Bio's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Grape King Bio's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Grape King Bio (TPE:1707) has a Market Cap of NT$13,347 Mil as of Aug. 23, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Grape King Bio and its competitors. According to the industry distribution chart, Grape King Bio ranks #433 out of 1021 companies in the Drug Manufacturers industry, placing it in the top 42.4%.
Is Grape King Bio's Market Cap too high?
Grape King Bio's current Market Cap is NT$13,347 Mil. Based on the distribution chart, Grape King Bio ranks #433 out of 1021 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Grape King Bio has a GF Score™ of 79/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Grape King Bio's Market Cap compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Grape King Bio ranks #433 out of 1021 companies for Market Cap. This puts Grape King Bio in the upper half of its industry. The industry median Market Cap is 234.76. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 234.76, based on 1,021 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Grape King Bio and its competitors. For the Drug Manufacturers industry, the median Market Cap is 234.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Grape King Bio's current Market Cap is NT$13,347 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grape King Bio stock overvalued right now?
Based on GuruFocus' analysis, Grape King Bio (TPE:1707) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$138.97, compared to a current price of NT$90.10 — trading 35.2% below its estimated fair value. The current Market Cap is NT$13,347 Mil. Grape King Bio's overall GF Score™ is 79/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Grape King Bio (TPE:1707), the current Market Cap is NT$13,347 Mil as of Aug. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Grape King Bio (TPE:1707) Overvalued in 2026?
Based on GuruFocus' analysis, Grape King Bio stock appears to be undervalued.
The current stock price of NT$90.10 is trading 35.2% below its estimated GF Value™ of NT$138.97.
GuruFocus considers Grape King Bio to be Significantly Undervalued.
Key valuation signals for TPE:1707:
Market Cap: NT$13,347 Mil
GF Value™: NT$138.97 vs. price of NT$90.10 (35.2% below fair value)
No single metric tells the full story. See the TPE:1707 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Grape King Bio Ltd is a specialty and generic drug manufacturing company engaged in producing and selling pharmaceutical preparations, patent medicines, liquid tonics, drinks, and healthy food. The company has three segments: MLM (Multi-Level Marketing), which is a direct seller of Pro-partner Inc, including the company's development and manufacturing products for Pro-partner Inc, the Distributors segment includes the company's self-owned brand products, and ODM/OEM (Original Design Manufacturer/Original Equipment Manufacturer) includes ODM/OEM in Taiwan and Shanghai. The group operates in three principal geographical areas - Taiwan, China, and Others, and it derives a majority of its revenue from Taiwan.
79GF Score
Get the complete analysis for TPE:1707
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1707 has been successfully added to your 
